A novel NFKB1 agonist remodels tumor microenvironment and activates dendritic cells to promote anti-tumor immunity in colorectal cancer
Our study identified a novel NFKB1 agonist that promotes anti-tumor immunity by remodeling the TME and activating DCs and that may provide a new way to overcome resistance to current anti-tumor immunotherapy in colorectal cancer.
Authors
- Steven X. Hou (ORCID: https://orcid.org/0000-0001-7583-2504)
- Zixiang Wang (ORCID: https://orcid.org/0000-0001-5252-9764)
- Ying Chen (ORCID: https://orcid.org/0000-0001-6303-5858)
- Ling Sun (ORCID: https://orcid.org/0000-0002-0910-7643)
- Qiaoming Li
Institutions
- Fudan University (CN)
- Children's Hospital of Fudan University (CN)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2025-05-20
- DOI
- https://doi.org/10.1186/s12967-025-06576-2
- Citations
- 1
- Primary Topic
- Immune Cell Function and Interaction
- Type
- article
- Field-Weighted Citation Impact
- 0.80
Funders
- National Natural Science Foundation of China
- Fudan University
- State Key Laboratory of Genetic Engineering
- Joint Fund of the National Natural Science Foundation of China and the Karst Science Research Center of Guizhou Province
- National Key Research and Development Program of China